Sonja Heuker, MD
Family Medicine · Cincinnati, OHNPI 1669435731
Payments from drug & device makers
Across 195 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Merz North America, Inc.$334
- Novo Nordisk$260
- Lilly USA, LLC$251
- Pfizer$177
- Bayer$150
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$752%
- Food & beverage$3,86998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $1,145 |
| Merz North America, Inc. | 4 | $334 |
| Novo Nordisk | 15 | $260 |
| Lilly USA, LLC | 17 | $251 |
| Pfizer | 10 | $177 |
| Bayer | 8 | $150 |
| Mannkind Corporation | 9 | $150 |
| Astellas Pharma US Inc | 7 | $123 |
| Boehringer Ingelheim | 8 | $123 |
| Exact Sciences | 6 | $117 |
| Xeris Pharmaceuticals, Inc. | 6 | $106 |
| GSK | 6 | $96 |
| Amgen | 5 | $81 |
| Amarin Pharma, Inc. | 4 | $73 |
| Corcept Therapeutics | 3 | $70 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| AstraZeneca(2 entities) | 4 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $53 |
| Sanofi-aventis U.S. LLC | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Abbott | 2 | $44 |
| Johnson & Johnson | 3 | $43 |
| Merck | 3 | $43 |
| Novartis | 2 | $35 |
| Avanir Pharmaceuticals, Inc. | 1 | $32 |
| Galderma Laboratories, L.p. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Valeritas, Inc. | 1 | $25 |
| Alk-abello, Inc | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Viiv Healthcare Company | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $20 |
| Insulet Corporation | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $12 |
| Cequr Corporation | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$118
How this compares
$3,944 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $62,176 |
| EliquisApixaban | 23 | $29,302 |
| XareltoRivaroxaban | 33 | $27,946 |
| JardianceEmpagliflozin | 16 | $19,654 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $12,755 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $10,741 |
| DuleraMometasone/Formoterol | 11 | $3,413 |
| Atorvastatin Calcium | 261 | $1,767 |
| Ibandronate Sodium | 55 | $1,523 |
| Gabapentin | 63 | $1,262 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 53 | $1,206 |
| Carbamazepine | 15 | $1,163 |
| Potassium Chloride | 50 | $1,109 |
| Metformin Hcl | 139 | $1,064 |
| Losartan Potassium | 177 | $1,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $260 | $62,17637 claims |
| PfizerEliquis | $177 | $29,30223 claims |
| Johnson & JohnsonXarelto | $43 | $27,94633 claims |
| Boehringer IngelheimJardiance | $123 | $19,65416 claims |
| GSKBreo Ellipta | $96 | $12,75516 claims |
| MerckDulera | $43 | $3,41311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Cincinnati
- Michael ButcherCincinnati$18.3M
- Paul NugentCincinnati$4.9M
- Rajesh DavitCincinnati$2M
- Michael HeileCincinnati$272K
- Michael NossCincinnati$265K
- Amy MechleyCincinnati$120K
- Melissa SchroerCincinnati$116K
- William CoxCincinnati$52K
- Frank PerrinoCincinnati$49K
- Sean LyndCincinnati$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.